VisionPoint Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

VisionPoint Advisory Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$238K	Sell	479 -285	-37%	-$126K	0.04%	414
2026 Q1	$341K	Sell	764 -38	-5%	-$17.7K	0.06%	294
2025 Q4	$364K	Buy	+802	New	+$346K	0.07%	265
2025 Q3	–	Sell	-520	Closed	-$232K	–	416
2025 Q2	$232K	Buy	+520	New	+$240K	0.05%	321
2024 Q3	–	Sell	-75	Closed	-$35.2K	–	769
2024 Q2	$35.2K	Buy	75 +24	+47%	+$10.4K	0.01%	328
2024 Q1	$21.3K	Buy	+51	New	+$21.6K	0.01%	374

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

MLL

Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

VisionPoint Advisory Group's VRTX Position: Q2 2026 in Review

VisionPoint Advisory Group reduced its Vertex Pharmaceuticals (VRTX) stake by 37% in Q2 2026, selling an estimated $126K and leaving 479 shares worth $238K. The position accounts for 0.04% of the portfolio, ranked #414.

VisionPoint Advisory Group first reported a position in VRTX in Q1 2024 and has held it in 6 quarters since. The position peaked at $364K in Q4 2025. 296 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

VisionPoint Advisory Group held 479 shares of Vertex Pharmaceuticals worth $238K as of Q2 2026.
VisionPoint Advisory Group sold 285 Vertex Pharmaceuticals shares in Q2 2026, an estimated $126K.
Vertex Pharmaceuticals made up 0.04% of VisionPoint Advisory Group's portfolio in Q2 2026, its #414 holding.
VisionPoint Advisory Group first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
VisionPoint Advisory Group's Vertex Pharmaceuticals position peaked at $364K in Q4 2025.
296 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on VisionPoint Advisory Group's 13F filing for Q2 2026, filed 7 Jul 2026.